BioMed X
BioMed X is a Heidelberg-based biomedical innovation hub founded in 2013 that runs 4-5 year collaborative research projects with global pharmaceutical companies (AbbVie, Novo Nordisk, Roche, Merck KGaA, Sanofi, Boehringer Ingelheim, and others) and foundations like the Gates Foundation, using crowdsourcing and a 15,000+ researcher Career Space platform to assemble project teams.
- Company typePrivate
- Founded2013
- HeadquartersHeidelberg, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
What BioMed X does
BioMed X is a privately held biomedical innovation hub founded in 2013 in Heidelberg, Germany, that operates at the interface between academia and the pharmaceutical industry. The company's core operating model combines crowdsourcing, design thinking, and structured boot camp selection to identify top early-career academic researchers worldwide and embed them in 4-5 year collaborative research projects. Sourcing runs through the proprietary BioMed X Career Space platform, which holds over 15,000 registered researchers, and is supplemented by 41 crowdsourcing calls and 42 boot camps executed since inception. BioMed X has created 35 research and startup teams and completed 19 research projects, with 74% of project IP acquired by partners.
The business serves two primary customer verticals: pharmaceutical companies (AbbVie, Novo Nordisk, Merck KGaA, Roche, Sanofi, Boehringer Ingelheim, Servier, Janssen, Daiichi Sankyo, Ono Pharmaceutical, Eli Lilly, AstraZeneca, Pfizer) and global health foundations (Bill & Melinda Gates Foundation). Revenue is generated through professional services-style industry partnerships and grant-funded research, with no publicly disclosed pricing. The company operates five locations (Heidelberg and New Haven research institutes, Ridgefield and Paris-Saclay startup incubators branded as XSeed Labs, and the XFem Labs women's health accelerator) and runs multiple programs including XBridge (industry-academic collaborations with Harvard) and the AION Labs joint venture for AI-driven antibody engineering.
The product portfolio combines physical research infrastructure with proprietary technology platforms. Notable technology assets include the BioMedAgent multi-agent LLM framework for autonomous biomedical data analysis, the T-FINDER Platform for T cell response analysis against cancer vaccines, and a T Cell Immunology Discovery Platform for cognate epitope mapping. Research spans oncology, immunology, platform technologies, and artificial intelligence, with active use cases in oral peptide formulation (Novo Nordisk, GLP-1 receptor agonists), neuroscience/anhedonia (AbbVie), AI-driven antibody engineering (Servier), multispecific biologics for cancer (Daiichi Sankyo), and AI-enabled modeling of diabetic kidney disease (Government of Barbados). Legal entity is BioMed X AG, a German Aktiengesellschaft, headquartered at Im Neuenheimer Feld 515, 69120 Heidelberg, with 11-50 employees.
BioMed X firmographics
Firmographics- Name
- BioMed X
- Legal name
- BioMed X AG
- Website
- https://bmedx.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BioMed X is a Heidelberg-based biomedical innovation hub founded in 2013 that runs 4-5 year collaborative research projects with global pharmaceutical companies (AbbVie, Novo Nordisk, Roche, Merck KGaA, Sanofi, Boehringer Ingelheim, and others) and foundations like the Gates Foundation, using crowdsourcing and a 15,000+ researcher Career Space platform to assemble project teams.
- Ownership category
- akta.pro rank
BioMed X industry classification
Industry- Product category
- Contract Biomedical Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where BioMed X is headquartered
LocationHeadquarters
- HQ city
- Heidelberg
- HQ country
- Germany
- HQ region
- Europe
Offices4 records
Markets served
BioMed X business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Pharmaceutical Industry Partnerships: BioMed X partners with pharma companies to conduct exploratory research on challenges identified by industry partners. Results and IP from research projects are transferred to pharmaceutical partners after completion.
- Foundation Grants: Supported by grants from foundations such as the Gates Foundation for specific research initiatives like women's health programs
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
BioMed X product offering
Product offeringCore offering
BioMed X operates a network of biomedical research institutes, startup incubators, and R&D accelerators that deliver sponsored exploratory research for pharmaceutical partners and global health funders. It identifies therapeutic and platform R&D challenges from industry partners, crowdsources global academic talent through its Career Space platform and boot camp selection process, embeds recruited research teams within its institutes in Heidelberg, New Haven, Paris-Saclay, and Ridgefield, and transfers the resulting research outputs and IP back to sponsors after 4-5 year project terms.
Product overview
BioMed X is a biomedical innovation hub that operates multiple research institutes (Heidelberg, New Haven), startup incubators (XSeed Labs in Ridgefield and Paris-Saclay), and specialized accelerators (XFem Labs for women's health). The company combines crowdsourcing with incubation, partnering with pharmaceutical companies to identify key challenges across therapeutic areas and recruit top academic talent to co-create solutions. Core offerings include the BioMed X Institute facilities, XSeed Labs startup incubators, XBridge industry-academic collaboration platform, the BioMedAgent AI framework for autonomous biomedical data analysis, and the T-FINDER Platform for T cell response analysis. Since 2013, they have created 35 research/startup teams, completed 19 projects, and performed 41 crowdsourcing calls.
Differentiator
Problem solved
Functional benefit
Brands
- XFem Labs: Women's health R&D accelerator launched in Heidelberg, Germany, with focus on non-hormonal contraceptives for low- and middle-income countries.
- XSeed Labs
- XBridge
- AION Labs
Products and services
- BioMed X Institute Heidelberg Biomedical research institute located in Heidelberg, Germany (Im Neuenheimer Feld 515, 69120 Heidelberg) that conducts crowdsourced, industry-partnered research projects across therapeutic areas and transfers results and IP to pharmaceutical partners after 4-5 year project terms.
- BioMed X Institute New Haven U.S.-based BioMed X research institute in New Haven, CT, hosting industry-partnered research teams including the AbbVie collaboration in immunology and tissue engineering that began in 2023.
- XSeed Labs Ridgefield Venture-creating incubator in Ridgefield, USA, operated in partnership with Boehringer Ingelheim to support biomedical startups and early-stage innovation teams emerging from BioMed X research.
- XSeed Labs Paris-Saclay BioMed X venture-creating incubator at Servier's Paris-Saclay campus combining AI and immunology expertise to advance next-generation biologics through startup creation.
- XFem Labs Heidelberg Women's health R&D accelerator in Heidelberg, Germany, that develops targeted therapeutics and technologies for women's health, including non-hormonal contraceptives for women in low- and middle-income countries, funded by foundation grants and partnerships.
- XBridge Program Program to facilitate structured research collaborations between academic investigators and pharmaceutical industry scientists via sponsored research agreements, initially piloted with Harvard University.
- BioMedAgent Multi-agent LLM framework with self-evolving capabilities for autonomous, tool-aware biomedical data analyses, integrating multiple data types (text, structured data, multimodal) to perform biomedical research workflows.
- BioMed X Career Space Global talent-sourcing platform with 15,000+ registered researchers that supports the identification, application, and boot camp selection of early-career academic researchers for BioMed X research projects.
Quantifiable outcome
- 74% Research Project IP Acquired by Partners
- +3 more outcomes
Companies that use BioMed X
Customer profileNamed customers15 records
Segments2 records
Ideal customer profiles4 records
BioMed X technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability9 records
Feature1 record
BioMed X partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, major and minor.
- Government of BarbadoscorePartnership with the Government of Barbados and European Union's PharmaNext Programme for AI-enabled modeling of early diabetic kidney disease in the Barbadian population. Project includes deep molecular profiling and AI-driven modeling.
- Harvard UniversitymajorXBridge framework pilot initiative to facilitate structured research collaborations between academic investigators and pharmaceutical industry scientists through sponsored research agreements.
- AbbViecoreNew neuroscience research collaboration in the USA focused on understanding anhedonia and identifying therapeutic targets. Project analyzes brain microcircuits and molecular mechanisms using interdisciplinary approaches.
- Novo NordiskcoreCollaboration to develop innovative oral peptide formulation technologies for GLP-1 receptor agonists. Research project titled 'Prolonged Retention of Oral Peptide Formulations in the Gut' aims to improve absorption and bioavailability.
- ServiercoreLaunch of first research team in France (XSeed Labs Paris-Saclay) to pioneer AI-driven antibody engineering. Partnership brings together AI and immunology expertise to advance next-generation biologics.
- Boehringer IngelheimcoreJoint XSeed Labs incubator in the U.S. expanded to support startup companies in biomedical innovation.
- Merck KGaA, Darmstadt, GermanycoreMultiple oncology and immunology research collaborations including extrachromosomal DNA in cancer research, with extensions of research programs over multiple years.
- RochemajorResearch collaboration in the field of immunology and AI for drug development.
- SanofimajorResearch collaboration on artificial intelligence for drug development.
- JanssenmajorImmunology research collaboration with expansion of strategic collaboration over time.
- Daiichi SankyomajorCollaboration for multispecific biologics in cancer therapy and new research team in immuno-oncology.
- Ono PharmaceuticalminorNew collaboration in cancer research (immuno-oncology) at BioMed X Institute Heidelberg.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
BioMed X competitors and assessment
Company assessmentBroad incumbents
- Charles River Laboratories: Large CRO providing outsourced drug discovery and preclinical services to pharma; broader portfolio but competes for the same outsourced exploratory R&D spend.
- IQVIA: Global life sciences services and clinical research organization; much broader but overlaps with BioMed X in pharma R&D outsourcing and informatics services.
Emerging players
- Recursion Pharmaceuticals: AI/ML-enabled drug discovery platform combining high-throughput biology with machine learning; competes for the same pharma partnership and licensing dollars as BioMed X's AI-led offerings.
- Wild Design (Wellcome Leap / Gates Foundation R&D): Foundation-backed biomedical research programs; comparable in using venture-style funding structures to drive translational science, and overlaps with BioMed X's XFem Labs Gates-funded work.
- Insitro: Machine learning-driven drug discovery company with major pharma partnerships (Bristol Myers Squibb, Eli Lilly); comparable in marrying AI, data, and pharma R&D collaborations.
- Exscientia: AI-driven small molecule discovery company with pharma collaborations (Sanofi, BMS, Roche); competes for AI-driven pharma R&D budgets alongside BioMed X.
Others
- Mila (Quebec AI Institute): Academic-industry AI research institute partnering with pharma; adjacent because of similar academia-industry bridge model and AI-focused research output, though not a commercial CRO.
Direct peers
- AION Labs: AI-driven drug discovery hub jointly run by BioMed X and several pharma companies (AstraZeneca, Pfizer, Merck, Teva, AWS); directly comparable mission of crowdsourced biomedical innovation, and is explicitly noted as 'Powered by BioMed X'.
- AbCellera Biologics: Antibody discovery and engineering platform with deep pharma partnerships; directly comparable to BioMed X's antibody engineering work with Servier and others.
- LabCentral: Biotech startup incubator co-located with academic and pharma partners in Cambridge, MA; directly comparable mission of providing shared infrastructure and sponsorship pipelines for early-stage biomedical ventures.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
BioMed X social profiles
Digital presenceBioMed X financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioMed X leadership team
Management profileNumber of profiles
Profiles3 records
BioMed X subsidiaries and ownership
Company hierarchySubsidiaries6 records
BioMed X funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioMed X M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioMed X
What does BioMed X do?
BioMed X operates a network of biomedical research institutes, startup incubators, and R&D accelerators that deliver sponsored exploratory research for pharmaceutical partners and global health funders. It identifies therapeutic and platform R&D challenges from industry partners, crowdsources global academic talent through its Career Space platform and boot camp selection process, embeds recruited research teams within its institutes in Heidelberg, New Haven, Paris-Saclay, and Ridgefield, and transfers the resulting research outputs and IP back to sponsors after 4-5 year project terms.
Is BioMed X a public or private company?
BioMed X is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BioMed X founded?
BioMed X was founded in 2013. It employs 11 to 50 people.
Where is BioMed X based?
BioMed X is headquartered in Heidelberg, Germany, in the Europe region.
How does BioMed X make money?
Two revenue lines are on record. Pharmaceutical Industry Partnerships are the primary driver. The others are foundation Grants.
Who are BioMed X's main competitors?
Broad incumbents on record are Charles River Laboratories and IQVIA. Emerging players are Recursion Pharmaceuticals, Wild Design (Wellcome Leap / Gates Foundation R&D), Insitro and Exscientia. Mila (Quebec AI Institute) is listed as an others. Direct peers are AION Labs, AbCellera Biologics and LabCentral.
Does BioMed X have an API?
No public API is recorded for BioMed X.
What industry is BioMed X in?
BioMed X's product category is Contract Biomedical Research Services. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 8731.